(Q34327769)

1 August 2017

title

Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease (English)

1 reference

1 August 2017

1 reference

1 reference

Chin B Eap

2

0 references

author name string

Muriel Noetzli

series ordinal

1

1 reference

1 August 2017

publication date

1 April 2013

1 reference

Clinical Pharmacokinetics

1 August 2017

published in

1 reference

1 August 2017

volume

52

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

225-241

1 reference

https://scigraph.springernature.com/pub.10.1007/s40262-013-0038-9

1 August 2017

exact match

0 references

cites work

Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Global prevalence of dementia: a Delphi consensus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

The epidemiology of the dementias: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Epidemiology of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Neurochemical basis for symptomatic treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

The significance of the cholinergic system in the brain during aging and in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Memantine for the treatment of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Genetics of Alzheimer's disease: an insight into presenilins and apolipoprotein E instigated neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

The pharmacogenomics of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Current status on Alzheimer disease molecular genetics: from past, to present, to future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Memantine in moderately-severe-to-severe Alzheimer's disease: a postmarketing surveillance study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Pharmacogenetics and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Targeting acetylcholinesterase and butyrylcholinesterase in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Active site gating and substrate specificity of butyrylcholinesterase and acetylcholinesterase: insights from molecular dynamics simulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Novel benzisoxazole derivatives as potent and selective inhibitors of acetylcholinesterase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Clinical pharmacokinetics of galantamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Galantamine: a review of its use in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Pharmacologic and Clinicopharmacologic Properties of SDZ ENA 713, a Centrally Selective Acetylcholinesterase Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Nicotinic component of galantamine in the regulation of amyloid precursor protein processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Cholinesterases: new roles in brain function and in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Pathologically activated therapeutics for neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Long-term course and effectiveness of combination therapy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Discontinuing donepezil or starting memantine for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

The metabolism and excretion of galantamine in rats, dogs, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Rivastigmine. A review of its use in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Rivastigmine exposure provided by a transdermal patch versus capsules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Pharmacokinetic rationale for the rivastigmine patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Pharmacokinetic study of memantine in healthy and renally impaired subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Role of organic cation transporters in drug-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Influence of urine pH and urinary flow on the renal excretion of memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Paraoxonase 1 gene polymorphisms do not influence the response to treatment in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Functional screening of drug target genes: m1 muscarinic acetylcholine receptor phenotypes in degenerative dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Apolipoprotein E in Alzheimer's disease and other neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Donepezil therapy in clinical practice: a randomized crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: relating to changes attributable to differences in apolipoprotein E phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Population pharmacokinetic study of memantine: effects of clinical and genetic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0038-9

Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine

21 January 2018

1 reference

12 December 2020

Donepezil: an anticholinesterase inhibitor for Alzheimer's disease.

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses

1 reference

12 December 2020

Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat

1 reference

12 December 2020

Memantine for dementia

1 reference

12 December 2020

Memantine hydrochloride: pharmacological and clinical profile.

1 reference

12 December 2020

Galantamine Population Pharmacokinetics in Patients with Alzheimer's Disease: Modeling and Simulations

1 reference

12 December 2020

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.

1 reference

12 December 2020

Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses

1 reference

12 December 2020

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis

1 reference

12 December 2020

Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease.

1 reference

12 December 2020

Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease.

1 reference

12 December 2020

Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects

1 reference

12 December 2020

Cholinesterase inhibitors for Alzheimer's disease

1 reference

12 December 2020

Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration

1 reference

12 December 2020

An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function

1 reference

12 December 2020

Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations.

1 reference

12 December 2020

Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers.

1 reference

12 December 2020

Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats

1 reference

12 December 2020

Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study

1 reference

12 December 2020

Update on the use of memantine in Alzheimer's disease

1 reference

12 December 2020

Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses

1 reference

12 December 2020

Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects

1 reference

12 December 2020

The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6

1 reference

12 December 2020

10.1007/S40262-013-0038-9

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1016362867

0 references

1 reference